These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19305696)

  • 1. Income-based drug coverage in British Columbia: the impact on private and public expenditures.
    Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e129-53. PubMed ID: 19305696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Income-Based Drug Coverage in British Columbia: Lessons for BC and the Rest of Canada.
    Morgan S; Evans RG; Hanley GE; Caetano PA; Black C
    Healthc Policy; 2006 Nov; 2(2):115-27. PubMed ID: 19305708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Income-based drug coverage in British Columbia: the impact on the distribution of financial burden.
    Hanley GE; Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e170-86. PubMed ID: 19305698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Income-based drug coverage in British Columbia: the impact on access to medicines.
    Caetano PA; Raymond CB; Morgan S; Yan L
    Healthc Policy; 2006 Nov; 2(2):e154-69. PubMed ID: 19305697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Income-based drug coverage in british columbia: towards an understanding of the policy.
    Morgan S; Coombes M
    Healthc Policy; 2006 Nov; 2(2):92-108. PubMed ID: 19305707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using policy simulation to predict drug plan expenditure when planning reimbursement changes.
    Dormuth CR; Burnett S; Schneeweiss S
    Pharmacoeconomics; 2005; 23(10):1021-30. PubMed ID: 16235975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan.
    Morgan SG
    Health Serv Res; 2002 Oct; 37(5):1243-66. PubMed ID: 12479495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants.
    Wang PS; Patrick AR; Dormuth C; Maclure M; Avorn J; Canning CF; Schneeweiss S
    J Ment Health Policy Econ; 2010 Mar; 13(1):37-44. PubMed ID: 20571181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Barer M; Reid RJ
    Health Policy; 2011 Jul; 101(2):185-94. PubMed ID: 21255859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription drug expenditures and population demographics.
    Morgan SG
    Health Serv Res; 2006 Apr; 41(2):411-28. PubMed ID: 16584456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):54-63. PubMed ID: 19305768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of evidence-based drug coverage policies on pharmaceutical r&d: a case study from british columbia.
    Morgan S; Cunningham C
    Healthc Policy; 2008 Feb; 3(3):e128-53. PubMed ID: 19305760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
    Morgan SG; Agnew JD; Barer ML
    Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications.
    Dormuth CR; Neumann P; Maclure M; Glynn RJ; Schneeweiss S
    Med Care; 2009 May; 47(5):508-16. PubMed ID: 19365295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of income-based deductibles on drug use and health care utilization among older adults.
    Law MR; Cheng L; Worthington H; Mamdani M; McGrail KM; Chan FKI; Majumdar SR
    CMAJ; 2017 May; 189(19):E690-E696. PubMed ID: 28507088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug expenditure trends in the Canadian provinces: magnitude and causes from 1998 to 2004.
    Morgan S
    Healthc Policy; 2005 Sep; 1(1):85-99. PubMed ID: 19308105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
    Daw JR; Morgan SG
    Health Policy; 2012 Jan; 104(1):19-26. PubMed ID: 21978939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
    Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
    Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
    CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.